As of Jul 29
| +0.01 / +0.17%|
The 5 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 6.00. The median estimate represents a +25.63% increase from the last price of 5.97.
The current consensus among 6 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.